More Videos
SPECIAL REPORT
MOST SHARED
- Health-Care Reform Does Little To Contain Costs: Analysts
- America Is On Sale
- Dodd: New Powers Could Prevent Economy Crash
- Trader Tax Sound Off
- If Mickey Mouse Has to Change—What Does That Say About You?
- Nov. 10: S&P Stocks Trading at New 52-Week Highs
- Home Prices Sank Further In Most Parts of US in 3rd Quarter
- Consumers' Mood Improves, But Will Sales Follow?
- Treasurys Head Lower as Auction Fails to Impress
- 'Peak Oil' Closer Than IEA Forecasts Show: Report
- Nov. 10: Unusual Volume Leaders
- Shadow Inventory Dwarfs Loan Mods
- The Lloyd's Prayer
- Playing Activision and Other Video Game Stocks: Analyst
- Expect 'At Least' Another 10-15% Upside: Fund Manager
- If Mickey Mouse Has to Change—What Does That Say About You?
- S&P Stocks Trading at New 52-Week Highs
- Passive Job Search Strategies
- Back Off, Regulators!
- Housing: 'Shadow Inventory' Dwarfs Loan Modifications
- Home Prices Decline Further In Most Parts of US
- UBS Faces Roadblock in Poaching More BofA Talent
- Jobless Rate to Hit 10.5%, Keeping Fed in Box: Poll
- Credit Card Firms Squeeze Customers as Rules Loom
- 'Thriller' Art: Warhol's Jackson Work Could Net $700,000
- Health Reform Does Little to Contains Costs: Analysts
- Ponzi Proceeds: Bidding on Madoff's Toys
- Quiz: Do You Know Your Coca-Cola Myths?
RSS FEED
Pharma's Market
Text Size 
 |
CNBC.com |
SGP [SGP
Loading...
()
] and Merck [MRK
Loading...
()
] are joint-venture partners on the pill which is a combination of Zocor and Zetia. Critics have alleged officials may have delayed releasing what many perceive as the negative results of the clinical trial.
You can see the filing for yourself here, but this is the lowdown:
SGP says Chairman and CEO Fred Hassan was told about the results on January 10th at 8 a.m. by Tom Koestler, the head of SGP's Research Institute. According to the filing, an executive VP was told at the exact same time, another exec veep learned about it half an hour later, and yet another EVP half an hour after that. Koestler was the first top-level guy to get the results on Jan. 7th at 2 p.m. The companies publicly released the results on January 14th at 8:05 a.m. ET according to the time stamp on the wire services we subscribe to at CNBC.
The filing also explains why SGP is reporting earnings much later than Merck this quarter. Recently I blogged that this is the first time in recent memory that the partners didn't come out on the same day.
The company says the later than usual date, Feb. 12th, is "to allow time to properly prepare consolidated financial results reflecting technical 'purchase accounting' adjustments for the November 2007 acquisition of Organon BioSciences N.V."
The filing also mentions that "the integration (with Organon) is progressing well."
*ENHANCE is the acronym for the study that compared Merck and Schering's cholesterol fighter Vytorin (a combo of Zocor and Zetia) to Zocor--which is now available as a generic--alone.
UPDATE: Interesting political/pharmaceutical factoid my producer, Ruth, just came across on the Associated Press wire. In a story about John McCain's health, it mentions that he's taking Vytorin.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes